Skip to main content
Top
Published in: Virology Journal 1/2018

Open Access 01-12-2018 | Research

High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles

Authors: Kasthuri Prakash, Gustaf E. Rydell, Simon B. Larsson, Maria Andersson, Gunnar Norkrans, Heléne Norder, Magnus Lindh

Published in: Virology Journal | Issue 1/2018

Login to get access

Abstract

Background

Hepatocytes infected by hepatitis B virus (HBV) produce different HBV RNA species, including pregenomic RNA (pgRNA), which is reverse transcribed during replication. Particles containing HBV RNA are present in serum of infected individuals, and quantification of this HBV RNA could be clinically useful.

Methods

In a retrospective study of 95 patients with chronic HBV infection, we characterised HBV RNA in serum in terms of concentration, particle association and sequence. HBV RNA was detected by real-time PCR at levels almost as high as HBV DNA.

Results

The HBV RNA was protected from RNase and it was found in particles of similar density as particles containing HBV DNA after fractionation on a Nycodenz gradient. Sequencing the epsilon region of the RNA did not reveal mutations that would preclude its binding to the viral polymerase before encapsidation. Specific quantification of precore RNA and pgRNA by digital PCR showed almost seven times lower ratio of precore RNA/pgRNA in serum than in liver tissue, which corresponds to poorer encapsidation of this RNA as compared with pgRNA. The serum ratio between HBV DNA and HBV RNA was higher in genotype D as compared with other genotypes.

Conclusions

The results suggest that HBV RNA in serum is present in viral particles with failing reverse transcription activity, which are produced at almost as high rates as viral particles containing DNA. The results encourage further studies of the mechanisms by which these particles are produced, the impact of genotype, and the potential clinical utility of quantifying HBV RNA in serum.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lampertico P, Agarwal K, Berg T, Buti M, HLA J, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.CrossRef Lampertico P, Agarwal K, Berg T, Buti M, HLA J, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98.CrossRef
2.
go back to reference Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRefPubMed Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRefPubMed
3.
go back to reference Larsson SB, Eilard A, Malmström S, Hannoun C, Dhillon AP, Norkrans G, et al. HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers. Liver Int. 2014;34:e238–45.CrossRefPubMed Larsson SB, Eilard A, Malmström S, Hannoun C, Dhillon AP, Norkrans G, et al. HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers. Liver Int. 2014;34:e238–45.CrossRefPubMed
4.
go back to reference Thompson AJV, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:1933–44.CrossRefPubMed Thompson AJV, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:1933–44.CrossRefPubMed
5.
go back to reference Cornberg M, Wong VW-S, Locarnini S, Brunetto M, Janssen HLA, Chan HL-Y. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398–411.CrossRefPubMed Cornberg M, Wong VW-S, Locarnini S, Brunetto M, Janssen HLA, Chan HL-Y. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398–411.CrossRefPubMed
6.
go back to reference van Bömmel F, Bartens A, Mysickova A, Hofmann J, Krüger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61:66–76.CrossRefPubMed van Bömmel F, Bartens A, Mysickova A, Hofmann J, Krüger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61:66–76.CrossRefPubMed
7.
go back to reference Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL. Hepatitis B virus Pregenomic RNA is present in Virions in plasma and is associated with a response to Pegylated interferon alfa-2a and Nucleos(t)ide analogues. J Infect Dis. 2015;213:224–32.CrossRefPubMed Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL. Hepatitis B virus Pregenomic RNA is present in Virions in plasma and is associated with a response to Pegylated interferon alfa-2a and Nucleos(t)ide analogues. J Infect Dis. 2015;213:224–32.CrossRefPubMed
8.
go back to reference Breitkreutz R, Zhang W, Lee M, Hoffmann A, Tokus M, Su Q, et al. Hepatitis B virus nucleic acids circulating in the blood: distinct patterns in HBs carriers with hepatocellular carcinoma. Ann N Y Acad Sci. 2001;945:195–206.CrossRefPubMed Breitkreutz R, Zhang W, Lee M, Hoffmann A, Tokus M, Su Q, et al. Hepatitis B virus nucleic acids circulating in the blood: distinct patterns in HBs carriers with hepatocellular carcinoma. Ann N Y Acad Sci. 2001;945:195–206.CrossRefPubMed
9.
go back to reference Rokuhara A, Matsumoto A, Tanaka E, Umemura T, Yoshizawa K, Kimura T, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol Springer-Verlag. 2006;41:785–90.CrossRef Rokuhara A, Matsumoto A, Tanaka E, Umemura T, Yoshizawa K, Kimura T, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol Springer-Verlag. 2006;41:785–90.CrossRef
10.
go back to reference Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat. 2000;7:258–67.CrossRefPubMed Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat. 2000;7:258–67.CrossRefPubMed
11.
go back to reference Malmström S, Larsson SB, Hannoun C, Lindh M. Hepatitis B Viral DNA Decline at Loss of HBeAg Is Mainly Explained by Reduced cccDNA Load – Down-Regulated Transcription of PgRNA Has Limited Impact. Ryu W-S, editor. PLoS ONE. 2012;7:e36349.CrossRefPubMedPubMedCentral Malmström S, Larsson SB, Hannoun C, Lindh M. Hepatitis B Viral DNA Decline at Loss of HBeAg Is Mainly Explained by Reduced cccDNA Load – Down-Regulated Transcription of PgRNA Has Limited Impact. Ryu W-S, editor. PLoS ONE. 2012;7:e36349.CrossRefPubMedPubMedCentral
12.
go back to reference Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of Precore mRNA synthesis is associated with mutations in the hepatitis B virus Core promoter. Virology. 2002;295:86–96.CrossRefPubMed Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of Precore mRNA synthesis is associated with mutations in the hepatitis B virus Core promoter. Virology. 2002;295:86–96.CrossRefPubMed
13.
go back to reference Désiré N, Ngo Y, Franetich JF, Dembele L, Mazier D, Vaillant JC, et al. Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms. J Viral Hepat. 2015;22:718–26.CrossRefPubMed Désiré N, Ngo Y, Franetich JF, Dembele L, Mazier D, Vaillant JC, et al. Definition of an HBsAg to DNA international unit conversion factor by enrichment of circulating hepatitis B virus forms. J Viral Hepat. 2015;22:718–26.CrossRefPubMed
14.
go back to reference Rydell GE, Prakash K, Norder H, Lindh M. Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro. Virology. 2017;509:67–70 Rydell GE, Prakash K, Norder H, Lindh M. Hepatitis B surface antigen on subviral particles reduces the neutralizing effect of anti-HBs antibodies on hepatitis B viral particles in vitro. Virology. 2017;509:67–70
15.
go back to reference Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65:700–10.CrossRefPubMed Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65:700–10.CrossRefPubMed
16.
go back to reference Beck J. Hepatitis B virus replication. WJG 2007;13:48. Beck J. Hepatitis B virus replication. WJG 2007;13:48.
17.
go back to reference Kidd AH, Kidd-Ljunggren K. A revised secondary structure model for the 3’-end of hepatitis B virus pregenomic RNA. Nucleic Acids Res. 1996;24:3295–301.CrossRefPubMedPubMedCentral Kidd AH, Kidd-Ljunggren K. A revised secondary structure model for the 3’-end of hepatitis B virus pregenomic RNA. Nucleic Acids Res. 1996;24:3295–301.CrossRefPubMedPubMedCentral
Metadata
Title
High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles
Authors
Kasthuri Prakash
Gustaf E. Rydell
Simon B. Larsson
Maria Andersson
Gunnar Norkrans
Heléne Norder
Magnus Lindh
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2018
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-018-0994-7

Other articles of this Issue 1/2018

Virology Journal 1/2018 Go to the issue